By NewsDesk  @bactiman63  AMIVAS Ireland Ltd., specialists in treatments for rare and neglected tropical diseases, including severe malaria, announced today the European Commission has granted approval...

The U.S. Food and Drug Administration approved Livtencity (maribavir) as the first drug for treating adults and pediatric patients (12 years of age and older and weighing at least 35 kilograms) with post-transplant...

By NewsDesk  @bactiman63  An analysis by the Center for Combating Corruption conclude in a new study that 4 out of 10 people purchased drugs that are ineffective and absent in modern treatment standards....

By NewsDesk  @bactiman63 Researchers this week published interim results in The New England Journal of Medicine from a Phase 3 study of the COVID-19 monoclonal antibody treatment sotrovimab, sponsored...

NewsDesk @bactiman63 Merck announced voluntarily recalling one lot of CUBICIN® (daptomycin for injection) 500mg for intravenous use, Lot 934778, Exp June 2022. Because treatment with CUBICIN is likely...

By NewsDesk  @bactiman63 United BioPharma announced this week that Shanghai Public Health Clinical Centre and Cheng Kung University’s Department of Microbiology and Immunology have joined United...

By NewsDesk  @bactiman63 Gilead Sciences, Inc. today announced the U.S. Food and Drug Administration (FDA) approved a new low-dose tablet dosage form of Biktarvy® (bictegravir 30 mg/emtricitabine 120...

Merck and Ridgeback Biotherapeutics announced recently that molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death at...

By NewsDesk  @infectiousdiseasenews From a press release from Juntendo University in Bunkyo City, Tokyo (computer translated): Malaria is transmitted from person to person through mosquitoes and causes...

By NewsDesk  @infectiousdiseasenews Recently, the Utah Department of Health became aware of a patient who ingested large doses of ivermectin in an attempt to treat symptoms of COVID-19. The patient suffered...